目的 分析咸陽市中心醫(yī)院179例丹參川芎嗪注射液的不合理使用情況，為規(guī)范臨床合理使用提供參考。方法 利用臨床用藥信息化軟件調(diào)取2019年8月26日-2019年9月25日使用丹參川芎嗪注射液出院患者179例，參照藥品說明書、相關(guān)專家共識或文獻(xiàn)，從適應(yīng)癥、用法用量、禁忌癥、配伍合理性等方面進(jìn)行點評。結(jié)果 使用丹參川芎嗪注射液的患者年齡主要在61~88歲，構(gòu)成比為51.40%；不合理類型共計124例，其中無適應(yīng)癥用藥的有111例，構(gòu)成比為89.52%；用法用量不合理共5例，單次劑量>10 mL有2例，未單獨使用有3例；存在禁忌癥5例，快速性心律失常有2例，出血傾向者有3例；存在配伍禁忌有3例，是與10%氯化鉀溶液配伍使用。14個科室使用了丹參川芎嗪注射液，神經(jīng)外科、呼吸內(nèi)科和急診醫(yī)學(xué)科的不合理率為100.00%。結(jié)論 丹參川芎嗪注射液在臨床科室使用中存在不合理現(xiàn)象，需多部門聯(lián)合采取措施規(guī)范其合理應(yīng)用。

Objective To investigate the unreasonable use of 179 cases of Danshen Chuanxiongqin Injection in Xianyang Central Hospital, and provide a reference for reasonable application of Danshen Chuanxiongqin Injection. Methods A total of 179 cases of inpatients who were administrated with Danshen Chuanxiongqin Injection from August 26, 2019 to September 25, 2019. The rationality was evaluated in terms of indications, usage and dosage, contraindications, repeated medications and others rational aspects, according to the drug instructions and related treatment guidelines or literature. Results Patients using Danshen Chuanxiongqin Injection were 61-88 years old, accounting for 51.40%. There were 124 cases of unreasonable drug use, in which 111 cases had no indication for medication, accounting for 89.52%. There were 5 cases of unreasonable usage and dosage, in which single dose >10 mL had 2 cases and not used alone had 3 cases. There were 5 cases of contraindications with 2 cases of tachyarrhythmia and 3 cases of bleeding tendency. There were 3 cases of incompatibility, and were compatible with 10% KCl solution. Danshen Chuanxiongqin Injection was used in 14 departments. The unreasonable utilization rates of Department of Neurosurgery, Department of Respiratory, and Department of Emergency Medicine were all 100.00%. Conclusion There is an unreasonable phenomenon in the clinical application of Danshen Chuanxiongqin Injection. It is necessary to take measures in multiple departments to regulate its rational application.

R969.3

陜西省中醫(yī)藥管理局2019-2020年度科研立項（2019-ZZ-JC046）